Back to Journals » Lung Cancer: Targets and Therapy
Lung Cancer: Targets and Therapy
An international, peer-reviewed, open access journal focusing on lung cancer research, identification of therapeutic targets and the optimal use of preventative and integrated treatment interventions to achieve improved outcomes, enhanced survival and quality of life for the cancer patient.
This journal is a member of and subscribes to the principles of the Committee on Publication Ethics (COPE).
- 5 records -
Shi J, Li J, Wang H, Li X, Wang Q, Zhao C, Cheng L, Han R, Chen P, Guo H, Tang Z, Zhou C, Zhang Z, Wu F
Published Date: 21 November 2023
Co-Occurring EGFR S645C and EGFR L858R in a Patient with Lung Adenocarcinoma Induced Primary Resistance to Osimertinib
Wang L, Quan F, Guo Z, Lu Z, Yang D, Shi M
Published Date: 9 October 2023
Lee AT, Ou SI
Published Date: 7 July 2023
The Additional Exclusions of ROS1 Fusions (In Addition to EGFR Mutation and ALK Fusions) in the Cemiplimab NSCLC FDA Indication (EMPOWER-Lung 1 and -Lung 3). Catching Up with Current Scientific View of Immunotherapy in Never-Smoker Predominant Actionable Driver Mutation Positive NSCLC?
Brazel D, Ou SI
Published Date: 23 June 2023
From ASCEND-5 to ALUR to ALTA-3, an Anti-Climactic End to the Era of Randomized Phase 3 Trials of Next-Generation ALK TKIs in the Crizotinib-Refractory Setting
Lee AT, Ou SI
Published Date: 22 June 2023